Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine + cisplatin as neoadjuvant therapy followed by adjuvant durvalumab in resectable muscle-invasive bladder cancer
2023-510015-19-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of durvalumab in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by AstraZeneca. Primary endpoints: pathologic complete response and event-free survival. Planned start Feb 2019; status: authorised.
02
Drugs
durvalumab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-510015-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510015-19-00.